223 related articles for article (PubMed ID: 16392142)
1. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer.
Moore CM; Nathan TR; Lees WR; Mosse CA; Freeman A; Emberton M; Bown SG
Lasers Surg Med; 2006 Jun; 38(5):356-63. PubMed ID: 16392142
[TBL] [Abstract][Full Text] [Related]
2. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model.
Rovers JP; Saarnak AE; Molina A; Schuitmaker JJ; Sterenborg HJ; Terpstra OT
Br J Cancer; 1999 Oct; 81(4):600-8. PubMed ID: 10574244
[TBL] [Abstract][Full Text] [Related]
4. Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck.
Copper MP; Tan IB; Oppelaar H; Ruevekamp MC; Stewart FA
Arch Otolaryngol Head Neck Surg; 2003 Jul; 129(7):709-11. PubMed ID: 12874068
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy using meta-tetrahydroxyphenylchlorin (Foscan) for the treatment of vulval intraepithelial neoplasia.
Campbell SM; Gould DJ; Salter L; Clifford T; Curnow A
Br J Dermatol; 2004 Nov; 151(5):1076-80. PubMed ID: 15541088
[TBL] [Abstract][Full Text] [Related]
6. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
[TBL] [Abstract][Full Text] [Related]
7. Effect of the TAT-RasGAP(317-326) peptide on apoptosis of human malignant mesothelioma cells and fibroblasts exposed to meso-tetra-hydroxyphenyl-chlorin and light.
Pittet O; Petermann D; Michod D; Krueger T; Cheng C; Ris HB; Widmann C
J Photochem Photobiol B; 2007 Jul; 88(1):29-35. PubMed ID: 17560792
[TBL] [Abstract][Full Text] [Related]
8. Interstitial photodynamic therapy for a symptom-targeted treatment of complex vascular malformations in the head and neck region.
Betz CS; Jäger HR; Brookes JA; Richards R; Leunig A; Hopper C
Lasers Surg Med; 2007 Aug; 39(7):571-82. PubMed ID: 17868106
[TBL] [Abstract][Full Text] [Related]
9. Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin.
Chang SC; Buonaccorsi G; MacRobert A; Bown SG
Int J Cancer; 1996 Aug; 67(4):555-62. PubMed ID: 8759616
[TBL] [Abstract][Full Text] [Related]
10. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
11. Optimization of treatment parameters for Foscan-PDT of basal cell carcinomas.
Betz CS; Rauschning W; Stranadko EP; Riabov MV; Albrecht V; Nifantiev NE; Hopper C
Lasers Surg Med; 2008 Jul; 40(5):300-11. PubMed ID: 18563776
[TBL] [Abstract][Full Text] [Related]
12. Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient.
Zimmermann A; Walt H; Haller U; Baas P; Klein SD
Cancer Chemother Pharmacol; 2003 Feb; 51(2):147-54. PubMed ID: 12647016
[TBL] [Abstract][Full Text] [Related]
13. Optimizing meso-tetra-hydroxyphenyl-chlorin-mediated photodynamic therapy for basal cell carcinoma.
Triesscheijn M; Ruevekamp M; Antonini N; Neering H; Stewart FA; Baas P
Photochem Photobiol; 2006; 82(6):1686-90. PubMed ID: 16984216
[TBL] [Abstract][Full Text] [Related]
14. Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC.
Krueger T; Altermatt HJ; Mettler D; Scholl B; Magnusson L; Ris HB
Lasers Surg Med; 2003; 32(1):61-8. PubMed ID: 12516073
[TBL] [Abstract][Full Text] [Related]
15. Biological responses of dog prostate and adjacent structures after meso-tetra-(m-hydroxyphenyl) chlorin and aluminum disulfonated phthalocyanine based photodynamic therapy.
Chang SC; Chern IF; Hsu YH
Proc Natl Sci Counc Repub China B; 1999 Oct; 23(4):158-66. PubMed ID: 10518316
[TBL] [Abstract][Full Text] [Related]
16. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study.
Nathan TR; Whitelaw DE; Chang SC; Lees WR; Ripley PM; Payne H; Jones L; Parkinson MC; Emberton M; Gillams AR; Mundy AR; Bown SG
J Urol; 2002 Oct; 168(4 Pt 1):1427-32. PubMed ID: 12352410
[TBL] [Abstract][Full Text] [Related]
17. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
18. New treatments for localized prostate cancer.
Marberger M; Carroll PR; Zelefsky MJ; Coleman JA; Hricak H; Scardino PT; Abenhaim LL
Urology; 2008 Dec; 72(6 Suppl):S36-43. PubMed ID: 19095127
[TBL] [Abstract][Full Text] [Related]
19. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
[TBL] [Abstract][Full Text] [Related]
20. Optimisation of illumination for photodynamic therapy with mTHPC on normal colon and a transplantable tumour in rats.
Tsutsui H; MacRobert AJ; Curnow A; Rogowska A; Buonaccorsi G; Kato H; Bown SG
Lasers Med Sci; 2002; 17(2):101-9. PubMed ID: 12111593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
